Camurus (CAMX) investor relations material

Company overview and strategy

• Rapidly growing commercial-stage company with leadership in opioid dependence treatment and expansion into the US market.

• Unique FluidCrystal technology platform validated through commercial products and licensing agreements.

• Advancing a late-stage pipeline targeting endocrinology and rare diseases with blockbuster potential.

• Achieved sustainable profitability since 2022 and maintains a strong cash position with no debt.

• Focused on ESG, achieving high sustainability ratings and structured value chain efforts.

Financial performance and outlook

• Revenues grew from SEK 601M in 2021 to SEK 2,265M in 2025, with profit before tax rising from SEK 73M to SEK 933M.

• 2026 outlook projects revenues of SEK 2.6–2.9B and operating results of SEK 0.9–1.2B, excluding potential licensing revenues.

• Strong operational performance supported by rapid financial growth and robust cash reserves (~SEK 3.7B).

Commercial execution and product portfolio

• Global leadership in long-acting opioid dependence treatment with Buvidal and Brixadi, showing double-digit growth and expanding market share.

• Oczyesa, a novel monthly subcutaneous octreotide, launched in Germany and approved in the EU/UK for acromegaly.

• Significant growth opportunities in high-potential European markets for Buvidal, with policy support and funding improvements underway.

• Targeting 100,000 Buvidal patients by 2027 and Brixadi peak market potential over $1B.